<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161582">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02074995</url>
  </required_header>
  <id_info>
    <org_study_id>CBVS857X2201</org_study_id>
    <nct_id>NCT02074995</nct_id>
  </id_info>
  <brief_title>Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects</brief_title>
  <official_title>Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15
      weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate safety &amp; tolerability of BVS857 in severe adult burn subjects</measure>
    <time_frame>Over 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy measure by change in Lean Body Mass (LBM)</measure>
    <time_frame>Groups 2,3&amp;4: Baseline, Day 35, Day 85 and Day 106</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total LBM is measured by dual energy X-ray absorptiometry (DXA) scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Cmax; The observed maximum plasma (or serum or blood) concentration following drug administration [mass / volume]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Tmax; The time to reach the maximum concentration after drug administration [time]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: AUClast; The area under the plasma (or serum or blood) concentration-time curve from time zero to the time of the last quantifiable concentration [mass x time / volume]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: AUCinf; The area under the plasma (or serum or blood) concentration-time curve from time zero to infinity [mass x time / volume]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: T1/2; The terminal elimination half-life [time]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:ay D1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: CL; The systemic (or total body) clearance from plasma (or serum or blood) following intravenous administration [volume / time]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Vz; The volume of distribution during the terminal elimination phase following intravenous administration [volume]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Vss; The volume of distribution at steady state following intravenous administration [volume]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Vz/F; The apparent volume of distribution during the terminal elimination phase following extravascular administration [volume]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: CL/F; The apparent systemic (or total body) clearance from plasma (or serum or blood) following extravascular administration [volume / time]</measure>
    <time_frame>Groups 1A&amp;1B: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hypercatabolic Status Related to Severe Burn</condition>
  <arm_group>
    <arm_group_label>BVS857 Grp 1A open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BVS857 Group 1B, 2, 3, 4 Double Blind</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group 1B, 2, 3, 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BVS857</intervention_name>
    <description>Group 1A&amp;1B receive first dose as IV then remaining doses as SC. Goups 2, 3 and 4 receive only SC doses.</description>
    <arm_group_label>BVS857 Grp 1A open label</arm_group_label>
    <arm_group_label>BVS857 Group 1B, 2, 3, 4 Double Blind</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Group 1B receive first dose as IV then remaining doses as SC. Goups 2, 3 and 4 receive only SC doses.</description>
    <arm_group_label>Placebo Group 1B, 2, 3, 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn must be â‰¥20% total body surface area with expected need for surgical
             intervention and not exceeding the sum of age plus burn size of 100 (Baux score)

          -  Dosing must occur within 8-12 days post-burn

          -  Subjects must weigh at least 45kgs (for group 1 with doses of 0.01mg/kg)  and be
             under 100 kg to participate in the study

        Exclusion Criteria:

          -  Spinal cord injury

          -  Hypoxic brain injury (Glasgow  Coma Scale  (GCS) &lt;8) at screening

          -  True conductive electric burn with suspected neurologic injury

          -  Diabetics with HbA1c &gt; 10%  or known history of hypoglycemia,

          -  History of  or active peripheral neuropathy or seizure disorder

          -  Systemic corticosteroids : &gt; 10mg/d of prednisone or equivalent, use of anabolic
             agents other than insulin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn, Severe burn, Lean body mass, Cachexia, Hypermetabolism, Catabolism, Wound healing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
